drugset / Trial / NCT04458259
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Non-randomizedSequentialOpen-labelTreatment
Summary
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
Timeline
- Start
- 2020-09-24
- Primary completion
- 2024-11-15
- Completion
- 2024-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |
| Subject | PF-07265807 | Small molecule | — | — |
| Subject | Sasanlimab | Monoclonal antibody | — | Subcutaneous |